Boston Scientific

Boston Scientific expands restructuring program

Wednesday, January 30, 2013 10:11 AM

Boston Scientific, a medical device company based in Natick, Mass., has announced an expansion of its 2011 restructuring program intended to build on the progress made under that program to strengthen its operational effectiveness and efficiencies and support new growth investments, which is expected to increase shareholder value. 

More... »


Cyberonics names KenKnight as vice president of emerging therapies

Friday, January 11, 2013 12:33 PM

Cyberonics, a medical technology company with core expertise in neuromodulation, has appointed Bruce H. KenKnight, Ph.D., as vice president of Emerging Therapies.

More... »


Boston Scientific enrolls first patient in coronary stent study featuring bioabsorbable polymer coating

Friday, November 30, 2012 12:13 PM

The first patient has been enrolled in Boston Scientific’s EVOLVE II clinical trial, designed to further assess the safety and effectiveness of the SYNERGY Stent System and support FDA and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.  

More... »

Boston Scientific to acquire Vessix Vascular

Friday, November 9, 2012 12:28 PM

Boston Scientific, a medical device company based in Natick, Mass., is extending its reach into the strategically critical renal denervation market by signing a definitive agreement to acquire Vessix Vascular, a Laguna Hills, Calif.-based held company developing novel RF balloon catheter and bipolar RF generator technology. 

More... »

Mahoney becomes CEO and president of Boston Scientific

Friday, November 2, 2012 11:52 AM

Boston Scientific, a global developer, manufacturer and marketer of medical devices, has named Michael F. Mahoney its new CEO and president. Mahoney succeeds interim CEO William H. (Hank) Kucheman. Mahoney has also been appointed to the Boston Scientific board of directors. 

More... »

Boston Scientific to acquire BridgePoint Medical

Thursday, September 20, 2012 07:30 AM

Boston Scientific, a global developer, manufacturer and marketer of medical devices, agreed to acquire BridgePoint Medical, a privately held company based in Minneapolis, Minn. The transaction is expected to close in the fourth quarter of 2012 subject to customary closing conditions.

More... »

Burrill wraps up life sciences industry for Q1 2012

Wednesday, April 4, 2012 03:00 PM

Burrill & Company, a diversified global financial services firm focused on the life sciences industry, has identified more than $2.6 billion in expected funding through nine translational research and early-stage initiatives announced since the end of February.

More... »

FDA approves first drug-eluting coronary stents

Monday, February 27, 2012 10:06 AM

The FDA has approved Boston Scientific’s Ion Paclitaxel-Eluting Platinum Chromium Coronary Stent System and Taxus Liberte Paclitaxel-Eluting Coronary Stent System for use in patients experiencing an acute myocardial infarction (AMI), or heart attack. 

More... »

Boston Scientific launches TruePath to treat blocked peripheral arteries

Wednesday, February 8, 2012 12:43 PM

Boston Scientific has launched the TruePath CTO device, designed to facilitate the crossing of chronic total occlusions (CTOs, or complete blockages) within the peripheral vasculature. The company will begin marketing the product immediately in the U.S. and expects to launch the product in Europe and other international markets in the first half of 2012.

More... »

Boston Scientific's PROMUS Element Stent receives FDA approval

Wednesday, November 23, 2011 10:31 AM

The FDA has approved Boston Scientific's PROMUS Element plus everolimus-eluting platinum chromium coronary stent system, the company's next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on an innovative platinum chromium (PtCr) platform with
the market-leading everolimus drug.  The company plans to begin marketing
the product in the U.S. immediately.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs